Global Ovarian Cancer Therapeutics Market 2015 Is Forecast to Rise at a Limited CAGR of 3.4% to $1.9 Billion in 2020 According to Market Research Store
Ovarian Cancer Therapeutics to 2020 - Late-Stage Pipeline Focuses on Improved Progression Free Survival and Targeted Therapies". The current Ovarian cancer therapeutics market is dominated by the use of generics – predominately carboplatin and paclitaxel, which are used in combination for the treatment of platinum-sensitive disease (both first-line and recurrent). Initial treatment with platinum-based therapy is usually effective, with approximately 70% of patients entering remission. However, even with extended progression free-survival of 24 months, almost all patients relapse, and after...
View full press release